Question 1

How does MissionArmy market a GLP-1 telehealth platform under increased FDA scrutiny of compounded semaglutide?

Accepted Answer

Content production for a GLP-1 telehealth platform starts with current FDA guidance as a reference at the brief stage, not as a compliance check after copy is live. Patient education content, platform positioning copy, and any clinical language in marketing materials are written within the boundaries of what the FDA has indicated is appropriate for compounded-GLP-1 marketing and reviewed against updated guidance before each piece is published. We treat this process as both a production standard and a trust signal: a platform that produces marketing content this way is demonstrating care to patients and regulators simultaneously, and we present it that way in the content itself.

Question 2

What FTC rules apply to marketing a "natural Ozempic alternative" supplement?

Accepted Answer

FTC structure-and-function claim limits apply to every piece of marketing copy for a supplement marketed in the GLP-1 adjacent or natural Ozempic alternative category. A supplement can claim to support metabolism, appetite management, or healthy weight management within the context of a balanced diet and exercise program. It cannot claim to treat obesity, replicate the clinical outcomes of a prescription GLP-1 medication, or prevent disease. The FTC has issued warning letters to supplement brands in exactly this category for both claim violations and missing creator disclosures. We build the distinction into every brief, every product page, and every creator asset before production starts.

Question 3

Does MissionArmy work with GLP-1 telehealth platforms, weight-loss supplement brands, or both?

Accepted Answer

Both. This page serves two distinct buyer types deliberately because both compete for similar searchers in several content categories and share overlapping compliance frameworks, while differing meaningfully in acquisition model, buyer persona, and trade press. A GLP-1 telehealth platform's marketing director and a DTC weight-loss supplement brand's head of performance marketing have different titles, different budgets, and different regulatory contexts, even though they may compete for the same patient or customer's attention. The free discovery call is where we identify which track applies and map the appropriate service mix.

Question 4

How do you compete with the huge volume of unpaid GLP-1 content already on social media?

Accepted Answer

Volume and posting frequency are not the competitive levers in a category this saturated. The unpaid creator content already covering GLP-1 and weight-loss topics is largely anecdotal, inconsistently accurate, and indifferent to FDA or FTC compliance. Brand content that is more useful, more clinically credible, and better sourced than the content around it earns the attention and citation that promotional volume cannot. For GLP-1 telehealth platforms, editorial content reviewed against FDA guidance and placed in MedCity News or Fierce Healthcare carries a weight that a TikTok anecdote does not. For supplement brands, product education that cites published research and stays inside FDA claim limits converts the skeptical buyer at a higher rate than a before-and-after comparison video.

Question 5

Which trade press and platforms does MissionArmy target for GLP-1 and weight-loss marketing?

Accepted Answer

Trade press splits by track. GLP-1 telehealth platforms target MedCity News and Fierce Healthcare. Weight-loss supplement brands target Nutritional Outlook and NutraIngredients-USA. On social platforms, Instagram and TikTok are the primary distribution channels for both tracks, with creator and UGC content FTC-disclosure-compliant from the brief stage. GEO and AEO targets the AI search environments where GLP-1 and weight-loss comparison queries are answered, including ChatGPT, Perplexity, and Google AI Overviews.

Question 6

How many people are actually using GLP-1 drugs right now, and how fast is that number growing?

Accepted Answer

Fast. KFF's November 2025 Health Tracking Poll found that 12 percent of US adults are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, with 18 percent saying they have taken one at some point. Both figures are roughly double what KFF measured 18 months earlier. Usage is highest among adults aged 50 to 64, at 22 percent current use, and women report current use at nearly double the rate of men. That speed of adoption is exactly why GLP-1 marketing claims, on both the telehealth and supplement side, are drawing faster and closer regulatory attention than almost any other healthcare category right now.

Get More Patients for Your GLP-1 Platform.

Two Tracks. Two Compliance Frameworks. One Competitive Landscape.

Track 1: GLP-1 Telehealth Platforms

Track 2: Weight-Loss Supplement Brands

Services That Drive Acquisition for GLP-1 and Weight-Loss Brands

How Fast This Category Has Grown, in Numbers.

Common Questions About GLP-1 and Weight-Loss Marketing.

One Call. We Map Your GLP-1 Patient and Customer Acquisition Gap.